Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
Donoghue Forlines LLC Takes $2.11 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY
06:14am, Sunday, 18'th Jan 2026
Donoghue Forlines LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) during the undefined quarter, according to the company in its most recent 13F filing with the Securities
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Analysts
03:48am, Thursday, 15'th Jan 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty-seven ratings firms that are currently covering the firm, Marke
Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf.
02:02am, Wednesday, 14'th Jan 2026
Alnylam Pharmaceuticals (NASDAQ: ALNY) used its presentation at the JPMorgan Healthcare Conference to outline what CEO Yvonne Greenstreet called the company's "next exciting chapter," highlighting a b
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:16pm, Monday, 12'th Jan 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale
01:33pm, Monday, 12'th Jan 2026
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) announced a new five-year roadmap, "Alnylam 2030," on Sunday, outlining the company's focus on scaling its operations.
Nisa Investment Advisors LLC Has $5.53 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY
05:54am, Monday, 12'th Jan 2026
Nisa Investment Advisors LLC grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 47.2% in the undefined quarter, according to the company in its most recent disclosure with the Securitie
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
05:00pm, Sunday, 11'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, “Alnylam 2030,” focused on scali
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Cerity Partners LLC
03:24am, Sunday, 11'th Jan 2026
Cerity Partners LLC boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 171.2% in the third quarter, according to the company in its most recent filing with the SEC. The
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
09:15am, Monday, 05'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate
Generali Asset Management SPA SGR Has $1.48 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
06:04am, Monday, 05'th Jan 2026
Generali Asset Management SPA SGR increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 6,368.0% in the undefined quarter, according to its most recent disclosure with the Securiti
Merit Financial Group LLC Has $1.93 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
05:16am, Monday, 05'th Jan 2026
Merit Financial Group LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 123.9% in the third quarter, according to the company in its most recent filing with the S
Osaic Holdings Inc. Purchases 2,158 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
05:07am, Friday, 02'nd Jan 2026
Osaic Holdings Inc. boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 132.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange C
This AI Infrastructure Stock Is 'Most Likely' To Be Added To S&P 500 In Q1 2026 According To Prediction Markets
03:13am, Friday, 02'nd Jan 2026
Vertiv Holdings Co. is expected to be next in line to join the S&P 500 during the first quarter of 2026, according to prediction markets.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages
03:50am, Sunday, 21'st Dec 2025
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) have earned an average rating of "Moderate Buy" from the twenty-eight research firms that are covering the company, Marketbeat
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
06:25pm, Friday, 19'th Dec 2025
CNBC's “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research.
